Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)

NCT01948986 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Impairment
Type 2 Diabetes Mellitus

Interventions

DRUG: Ertugliflozin

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]